I don’t know Ezra yet but since he’s taking the time to blog (which I hugesly respect) and share thoughts I thought I’d take him up on his challenge and also spill the beans on my secrets. On blogging I blog because I love it. My other secret on blogging? MORE
By the end of this year, for the first time, patients with certain deadly types of blood cancer might have a new option, CAR-T cell therapy , to prolong their life. Immunotherapy could further entrench itself as a mainstay of cancer treatment. MORE
Ahead of schedule, Novartis has received the first-ever approval of a genetically modified living cell therapy called CAR-T, which uses a cancer patient’s own immune cells as the medicine. MORE
The randomized controlled trial has long been held up as the gold standard for testing new drugs. But the nation’s top drug evaluator, Janet Woodcock, believes they aren’t necessary for all new experimental treatments. MORE
It’s always been Xconomy’s mission to reach audiences—both here on our website, and at our many live events around the country—with deep insights into the innovation process, divined from experts embedded in the world’s most important hubs of high-tech entrepreneurship. MORE
For many years, doctors and researchers have known that cancers in different parts of the body can share genetic abnormalities. For the first time, the FDA has approved a drug based on those abnormalities and not on the organ in which the cancer originated. MORE
Boston blog main Boston top stories Boulder/Denver blog main Detroit blog main Indiana blog main National National blog main National top stories New York blog main Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle blog main Texas blog main Wisconsin blog main Affordable Care Act Alnylam Pharmaceuticals Andrew Witty Arrowhead Pharmaceuticals Bill Cassidy Biogen Biotech Burrill & Co. MORE
Boston blog main Boulder/Denver blog main Detroit blog main Indiana blog main National blog main National top stories New York blog main Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle Seattle blog main Texas blog main Wisconsin blog main Apollo Investment Fund Dylan Cox Limited Partners M&A New Enterprise Associates PitchBook Private Equity VC MORE
Food delivery startups are catching on with more consumers, and that demand is whetting investor appetites. The $400 million that grocery delivery startup Instacart raised in March marked the largest deal for a U.S. food technology company in the first half of the year, according to new data from online investment marketplace AgFunder. MORE
Novartis said Wednesday that it would not charge for its newly approved cellular immunotherapy, tisagenlecleucel (Kymriah)—the first so-called CAR-T product to ever come to market—if it fails to help patients within a month. MORE
In mid-October, eleven college students will be flying to California for an opportunity that would be the envy of any Ivy League MBA candidate—they’ll meet the venture capital firm partners who will personally mentor them throughout the school year. MORE
With President Trump holed up in New Jersey, rattling his saber at Kim Jong-un and Mitch McConnell and ignoring his own commission’s advice on the opioid crisis, there was still life sciences news from the nation’s capital. The FDA reported that generic drug approvals are set to hit a record ; the agency under Commissioner Scott Gottlieb has moved this summer to increase generic competition and lower the nation’s high drug prices. MORE
View the Slideshow It is a time of great transitions in the technology and business world. Key advances in areas like machine intelligence, agriculture, and healthcare seem poised to transform society—and everyday life. MORE
According to several news reports, the Trump administration will nominate Scott Gottlieb to be the new commissioner of the FDA, a selection that had the life sciences industry breathing a sigh of relief Friday afternoon. MORE
It’s 4.50am. Sunday morning. And I couldn’t sleep. I have much on my mind since I just returned from a week on the road. 5 days. 3 cities. Late night Mexican food. Beers. Airports. Delays. I left on a Sunday. I had to miss a full day with my family, camping in the mountains. MORE
Boston blog main Boulder/Denver blog main Detroit blog main Indiana blog main National National blog main National top stories New York blog main Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle blog main Texas blog main Wisconsin blog main Accelerator Corp. MORE
[ Note: Ben Fidler coauthored this report.] The American Society of Clinical Oncology conference is wrapping up, and the closely-watched medical meeting-slash-hype machine produced its usual array of data. MORE
Boston Boston blog main Boston top stories Boulder/Denver blog main Detroit blog main Indiana blog main National blog main National top stories New York blog main Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle blog main Texas blog main Wisconsin blog main Life Sciences xconomyawardsboston MORE
View the Slideshow The finalists in the Young Innovator category of the 2017 Xconomy Awards show that it’s never too early in life to start a company or invent a new technology. MORE
The CEO of a major U.S. pharmaceutical company was in the news this week, but for a change not because of the cost of drugs. Merck CEO Kenneth Frazier (pictured) was the first of what quickly became a line of CEOs to exit President Trump’s manufacturing council, leading to its dissolution altogether. MORE
I used to love blogging. Blogging proved to be a great way to hone my ideas, have public conversations with people and as it turns out – build meaningful relationships through public dialog that spilled over into the real world. Somewhere along the way blogging changed. Fred Wilson said as much in his blog post today, too. I guess it’s just a reality of blogging and I accept that. I like “single take” blogging. MORE
The company said the redesign came after finding that users were interested in using its tools to create blog-like travel and trip journals, rather than the original, animated slideshows the tool provided. networking social blogging travel iphone hipgeo MORE
Ethereum co-founder Joe Lubin is calm and soft-spoken when he shares his vision of how blockchain technology and digital currencies could transform the Internet, the global economy, and many aspects of our daily lives. But what he’s talking about could become a raging tempest, and it’s worth paying attention to—especially given the vast sums of money pouring into the sector. Companies have raised more than $1.25 MORE
It’s been more than a year since an infamous party with hired models in cocktail dresses captured the biotech community’s attention at the 2016 J.P. Morgan conference. There has been plenty of talk since about closing biotech’s notable gender gap. At this year’s J.P MORE
Biotech CEOs Jeremy Levin and Steve Holtzman have watched the violence in Charlottesville, VA , and its continuing aftermath with disgust. But they aren’t just upset about the rally, the violence and death, and President Trump’s equivocating blame of “many sides.” Levin, of Ovid Therapeutics (NASDAQ: OVID ), and Holtzman, of Decibel Therapeutics, have been disappointed with their peers. MORE
It’s not a stretch to say that Greta Oberhofer is alive thanks to the genetically modified cell therapy called CAR-T. At three and a half months old, she was diagnosed with acute lymphoblastic leukemia, or ALL, an aggressive blood cancer. At 10 months old, she had a bone marrow transplant, which required chemotherapy. She had a bad reaction: Her kidney and liver shut down, and fluid built up in her heart and lungs. She was on a breathing machine. MORE
Blogs. By definition, you read blogs. People often ask me why I started blogging. I often get the question from people, “I’d like to blog, but I don’t really know what to talk about?&# My suggestion is to blog about your industry. You need a blog. MORE
Gene editing took an important step this week when a group of U.S. researchers used CRISPR-Cas9 technology to correct a genetic error in dozens of human embryos without complications. It’s a significant achievement, but amidst the hype, it’s worth cautioning just how much work has to be done before the technology leads to a safe and effective human therapeutic. Years of clinical testing, and likely unforeseen twists and turns, lay ahead, with many more biological mysteries to solve along the way. MORE
Entrepreneur-turned-venture capitalist Vinod Khosla made big headlines almost six years ago when he wrote a blog post called “Do We Need Doctors or Algorithms?” MORE
6 or 7 years ago when TechCrunch was at its peak market share (they are still strong but many more tech blogs have also popped up) there was a term for getting covered there called “the TechCrunch bounce.” that they probably read the main tech blogs. MORE
Blogging Related Topics 
Both Sides of the Table
JULY 14, 2015
I don’t know Ezra yet but since he’s taking the time to blog (which I hugesly respect) and share thoughts I thought I’d take him up on his challenge and also spill the beans on my secrets. On blogging I blog because I love it. My other secret on blogging?
Both Sides of the Table
NOVEMBER 18, 2012
It’s 4.50am. Sunday morning. And I couldn’t sleep. I have much on my mind since I just returned from a week on the road. 5 days. 3 cities. Late night Mexican food. Beers. Airports. Delays. I left on a Sunday. I had to miss a full day with my family, camping in the mountains.
socalTECH
JANUARY 11, 2012
The company said the redesign came after finding that users were interested in using its tools to create blog-like travel and trip journals, rather than the original, animated slideshows the tool provided. networking social blogging travel iphone hipgeo
Both Sides of the Table
JANUARY 18, 2015
I used to love blogging. Blogging proved to be a great way to hone my ideas, have public conversations with people and as it turns out – build meaningful relationships through public dialog that spilled over into the real world. Somewhere along the way blogging changed. Fred Wilson said as much in his blog post today, too. I guess it’s just a reality of blogging and I accept that. I like “single take” blogging.
Xconomy
SEPTEMBER 26, 2017
We are excited to announce the recipients of the first-ever Xconomy Awards.
Xconomy
AUGUST 17, 2017
View the Slideshow The finalists in the Young Innovator category of the 2017 Xconomy Awards show that it’s never too early in life to start a company or invent a new technology.
Xconomy
MAY 23, 2017
For many years, doctors and researchers have known that cancers in different parts of the body can share genetic abnormalities. For the first time, the FDA has approved a drug based on those abnormalities and not on the organ in which the cancer originated.
Xconomy
MAY 31, 2017
What does it take to keep highly skilled cybersecurity employees? Salary and benefits are table-stakes.
Xconomy
MAY 30, 2017
The randomized controlled trial has long been held up as the gold standard for testing new drugs. But the nation’s top drug evaluator, Janet Woodcock, believes they aren’t necessary for all new experimental treatments.
Xconomy
JULY 12, 2017
The first ever approval of a new kind of cancer immunotherapy called CAR-T is one step closer.
Xconomy
MARCH 23, 2017
It’s been more than a year since an infamous party with hired models in cocktail dresses captured the biotech community’s attention at the 2016 J.P. Morgan conference. There has been plenty of talk since about closing biotech’s notable gender gap. At this year’s J.P
Xconomy
AUGUST 31, 2017
Novartis said Wednesday that it would not charge for its newly approved cellular immunotherapy, tisagenlecleucel (Kymriah)—the first so-called CAR-T product to ever come to market—if it fails to help patients within a month.
Xconomy
OCTOBER 9, 2017
Ethereum co-founder Joe Lubin is calm and soft-spoken when he shares his vision of how blockchain technology and digital currencies could transform the Internet, the global economy, and many aspects of our daily lives. But what he’s talking about could become a raging tempest, and it’s worth paying attention to—especially given the vast sums of money pouring into the sector. Companies have raised more than $1.25
Xconomy
AUGUST 8, 2017
Boston Boston blog main Boston top stories Boulder/Denver blog main Detroit blog main Indiana blog main National blog main National top stories New York blog main Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle blog main Texas blog main Wisconsin blog main Life Sciences xconomyawardsboston
Xconomy
AUGUST 30, 2017
Ahead of schedule, Novartis has received the first-ever approval of a genetically modified living cell therapy called CAR-T, which uses a cancer patient’s own immune cells as the medicine.
Xconomy
AUGUST 18, 2017
The CEO of a major U.S. pharmaceutical company was in the news this week, but for a change not because of the cost of drugs. Merck CEO Kenneth Frazier (pictured) was the first of what quickly became a line of CEOs to exit President Trump’s manufacturing council, leading to its dissolution altogether.
Xconomy
JULY 28, 2017
Boston blog main Boulder/Denver blog main Detroit blog main Indiana blog main National National blog main National top stories New York blog main Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle blog main Texas blog main Wisconsin blog main Accelerator Corp.
Xconomy
AUGUST 24, 2017
Biotech CEOs Jeremy Levin and Steve Holtzman have watched the violence in Charlottesville, VA , and its continuing aftermath with disgust. But they aren’t just upset about the rally, the violence and death, and President Trump’s equivocating blame of “many sides.” Levin, of Ovid Therapeutics (NASDAQ: OVID ), and Holtzman, of Decibel Therapeutics, have been disappointed with their peers.
Xconomy
AUGUST 28, 2017
It’s clear at this point that patients are no longer just subjects in clinical trials.
Xconomy
APRIL 19, 2017
View the Slideshow It is a time of great transitions in the technology and business world. Key advances in areas like machine intelligence, agriculture, and healthcare seem poised to transform society—and everyday life.
Xconomy
JUNE 6, 2017
[ Note: Ben Fidler coauthored this report.] The American Society of Clinical Oncology conference is wrapping up, and the closely-watched medical meeting-slash-hype machine produced its usual array of data.
Xconomy
SEPTEMBER 22, 2017
Boston blog main Boston top stories Boulder/Denver blog main Detroit blog main Indiana blog main National National blog main National top stories New York blog main Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle blog main Texas blog main Wisconsin blog main Affordable Care Act Alnylam Pharmaceuticals Andrew Witty Arrowhead Pharmaceuticals Bill Cassidy Biogen Biotech Burrill & Co.
Xconomy
MARCH 10, 2017
According to several news reports, the Trump administration will nominate Scott Gottlieb to be the new commissioner of the FDA, a selection that had the life sciences industry breathing a sigh of relief Friday afternoon.
Xconomy
SEPTEMBER 25, 2017
Food delivery startups are catching on with more consumers, and that demand is whetting investor appetites. The $400 million that grocery delivery startup Instacart raised in March marked the largest deal for a U.S. food technology company in the first half of the year, according to new data from online investment marketplace AgFunder.
Xconomy
OCTOBER 10, 2017
In mid-October, eleven college students will be flying to California for an opportunity that would be the envy of any Ivy League MBA candidate—they’ll meet the venture capital firm partners who will personally mentor them throughout the school year.
Xconomy
SEPTEMBER 19, 2017
It’s not a stretch to say that Greta Oberhofer is alive thanks to the genetically modified cell therapy called CAR-T. At three and a half months old, she was diagnosed with acute lymphoblastic leukemia, or ALL, an aggressive blood cancer. At 10 months old, she had a bone marrow transplant, which required chemotherapy. She had a bad reaction: Her kidney and liver shut down, and fluid built up in her heart and lungs. She was on a breathing machine.
Both Sides of the Table
JANUARY 27, 2013
6 or 7 years ago when TechCrunch was at its peak market share (they are still strong but many more tech blogs have also popped up) there was a term for getting covered there called “the TechCrunch bounce.” that they probably read the main tech blogs.
Xconomy
JUNE 26, 2017
By the end of this year, for the first time, patients with certain deadly types of blood cancer might have a new option, CAR-T cell therapy , to prolong their life. Immunotherapy could further entrench itself as a mainstay of cancer treatment.
Xconomy
JUNE 22, 2017
It’s always been Xconomy’s mission to reach audiences—both here on our website, and at our many live events around the country—with deep insights into the innovation process, divined from experts embedded in the world’s most important hubs of high-tech entrepreneurship.
Xconomy
AUGUST 4, 2017
Gene editing took an important step this week when a group of U.S. researchers used CRISPR-Cas9 technology to correct a genetic error in dozens of human embryos without complications. It’s a significant achievement, but amidst the hype, it’s worth cautioning just how much work has to be done before the technology leads to a safe and effective human therapeutic. Years of clinical testing, and likely unforeseen twists and turns, lay ahead, with many more biological mysteries to solve along the way.
Xconomy
AUGUST 16, 2017
Boston blog main Boulder/Denver blog main Detroit blog main Indiana blog main National blog main National top stories New York blog main Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle Seattle blog main Texas blog main Wisconsin blog main Apollo Investment Fund Dylan Cox Limited Partners M&A New Enterprise Associates PitchBook Private Equity VC
Xconomy
AUGUST 11, 2017
With President Trump holed up in New Jersey, rattling his saber at Kim Jong-un and Mitch McConnell and ignoring his own commission’s advice on the opioid crisis, there was still life sciences news from the nation’s capital. The FDA reported that generic drug approvals are set to hit a record ; the agency under Commissioner Scott Gottlieb has moved this summer to increase generic competition and lower the nation’s high drug prices.
INDUSTRY INSIGHTS YOUR PEERS ARE READING
140 
Let's personalize your content